Literature DB >> 591977

Increased myofibrillar protein catabolism in Duchenne muscular dystrophy measured by 3-methylhistidine excretion in the urine.

R O McKeran, D Halliday, P Purkiss.   

Abstract

Myofibrillar protein catabolic rate was calculated in seven patients with Duchenne muscular dystrophy from the amount of 3-methylhistidine excreted in the urine, and found to be over three times that found in a control series when expresses as the percentage of myofibrillar protein catabolised per day. It is suggested that measurement of myofibrillar protein catabolic rate may add a useful parameter in the study of muscle disorders.

Entities:  

Mesh：

Substances：

Year:  1977        PMID： 591977      PMCID： PMC492880          DOI： 10.1136/jnnp.40.10.979

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN： 0022-3050            Impact factor:   10.154


  12 in total

1.  The measurement of creatinine in plasma and urine.

Authors:  K D EDWARDS; H M WHYTE
Journal:  Aust J Exp Biol Med Sci       Date:  1958-08

2.  The relationship of body composition to oxygen consumption and creatinine excretion in healthy and wasted men.

Authors:  R J RYAN; J D WILLIAMS; B M ANSELL; L M BERNSTEIN
Journal:  Metabolism       Date:  1957-07       Impact factor: 8.694

3.  Distinction between Duchenne and other muscular dystrophies by ribosomal protein synthesis.

Authors:  V Ionasescu
Journal:  J Med Genet       Date:  1975-03       Impact factor: 6.318

4.  Metabolism of 3-methylhistidine in man.

Authors:  C L Long; L N Haverberg; V R Young; J M Kinney; H N Munro; J W Geiger
Journal:  Metabolism       Date:  1975-08       Impact factor: 8.694

5.  Comparison of ribosomal protein synthesis in Becker and Duchenne muscular dystrophies.

Authors:  V Ionasescu; H Zellweger; W F McCormick; T W Conway
Journal:  Neurology       Date:  1973-03       Impact factor: 9.910

6.  A new approach for carrier detection in Duchenne muscular dystrophy. Protein synthesis of muscle polyribosomes in vitro.

Authors:  V Ionasescu; H Zellweger; T W Conway
Journal:  Neurology       Date:  1971-07       Impact factor: 9.910

7.  Potential use of 3-methylhistidine excretion as an index of progressive reduction in muscle protein catabolism during starvation.

Authors:  V R Young; L N Havenberg; C Bilmazes; H N Munro
Journal:  Metabolism       Date:  1973-11       Impact factor: 8.694

8.  Metabolism of administered 3-methylhistidine. Lack of muscle transfer ribonucleic acid charging and quantitative excretion as 3-methylhistidine and its N-acetyl derivative.

Authors:  V R Young; S D Alexis; B S Baliga; H N Munro; W Muecke
Journal:  J Biol Chem       Date:  1972-06-10       Impact factor: 5.157

9.  Amino acids of plasma and urine in diseases of muscle.

Authors:  W J Bank; L P Rowland; J Ipsen
Journal:  Arch Neurol       Date:  1971-02

10.  Measurement of muscle protein synthetic rate from serial muscle biopsies and total body protein turnover in man by continuous intravenous infusion of L-(alpha-15N)lysine.

Authors:  D Halliday; R O McKeran
Journal:  Clin Sci Mol Med       Date:  1975-12
View more
  11 in total

1.  Activated calcineurin ameliorates contraction-induced injury to skeletal muscles of mdx dystrophic mice.

Authors:  Nicole Stupka; David R Plant; Jonathan D Schertzer; Tennent M Emerson; Rhonda Bassel-Duby; Eric N Olson; Gordon S Lynch
Journal:  J Physiol       Date:  2006-06-22       Impact factor: 5.182

Review 2.  Contractile proteins in muscle disease.

Authors:  P Cummins
Journal:  J Muscle Res Cell Motil       Date:  1983-02       Impact factor: 2.698

3.  Clinical usefulness of urinary 3-methylhistidine excretion in indicating muscle protein breakdown.

Authors:  M Elia; A Carter; S Bacon; C G Winearls; R Smith
Journal:  Br Med J (Clin Res Ed)       Date:  1981-01-31

4.  Proteases in normal and diseased human skeletal muscle: a preliminary histochemical survey.

Authors:  M G White; P J Stoward; K N Christie; J M Anderson
Journal:  Histochem J       Date:  1985-07

5.  Decrease in urinary excretion of 3-methylhistidine by patients with Duchenne muscular dystrophy during glucocorticoid treatment.

Authors:  H Kawai; K Adachi; Y Nishida; T Inui; C Kimura; S Saito
Journal:  J Neurol       Date:  1993       Impact factor: 4.849

6.  Structural and functional alterations of muscle fibres in the novel mouse model of facioscapulohumeral muscular dystrophy.

Authors:  Giuseppe D'Antona; Lorenza Brocca; Orietta Pansarasa; Chiara Rinaldi; Rossella Tupler; Roberto Bottinelli
Journal:  J Physiol       Date:  2007-09-13       Impact factor: 5.182

7.  Abnormal collagen metabolism in cultured skin fibroblasts from patients with Duchenne muscular dystrophy.

Authors:  H P Rodemann; K Bayreuther
Journal:  Proc Natl Acad Sci U S A       Date:  1984-08       Impact factor: 11.205

8.  3-Methylhistidine excretion as an index of myofibrillar protein catabolism in neuromuscular disease.

Authors:  R O McKeran; D Halliday; P Purkiss; P Royston
Journal:  J Neurol Neurosurg Psychiatry       Date:  1979-06       Impact factor: 10.154

9.  Decreased lysosomal dipeptidyl aminopeptidase I activity in cultured human skin fibroblasts in Duchenne's muscular dystrophy.

Authors:  B B Gelman; L Papa; M H Davis; E Gruenstein
Journal:  J Clin Invest       Date:  1980-06       Impact factor: 14.808

10.  Serum proteomic profiling reveals fragments of MYOM3 as potential biomarkers for monitoring the outcome of therapeutic interventions in muscular dystrophies.

Authors:  Jérémy Rouillon; Jérôme Poupiot; Aleksandar Zocevic; Fatima Amor; Thibaut Léger; Camille Garcia; Jean-Michel Camadro; Brenda Wong; Robin Pinilla; Jérémie Cosette; Anna M L Coenen-Stass; Graham Mcclorey; Thomas C Roberts; Matthew J A Wood; Laurent Servais; Bjarne Udd; Thomas Voit; Isabelle Richard; Fedor Svinartchouk
Journal:  Hum Mol Genet       Date:  2015-06-09       Impact factor: 6.150
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.